Compare Aurora Cannabis Inc (ACB) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aurora Cannabis Inc vs BioNano Genomics Inc — how do they compare? Aurora Cannabis Inc trades at $3.66 (market cap $223.59M), while BioNano Genomics Inc trades at $1.17 (market cap $13.66M). The key difference: Aurora Cannabis Inc is far larger — about 16.4× BioNano Genomics Inc's market cap, and Aurora Cannabis Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| ACB | BNGO | |
|---|---|---|
Market Cap | $223.59M | $13.66M |
Sector | Health | Health |
52-Week High | $6.23 | $4.92 |
52-Week Low | $2.58 | $1.06 |
Enterprise Value | $168.09M | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $3.63, up 25.61% amid a hostile takeover bid from Curaleaf at a 45% premium. The stock shows mixed signals with a neutral technical outlook, while fundamentals reveal revenue growth to $343.29M in 2025 but a net income margin of -38.25% and negative ROE. Cash flow improved to a net positive $1.83M in 2025, though 2026 projections indicate renewed losses.
The takeover offer presents a near-term catalyst, but standalone risks persist including profitability challenges and competitive pressures. Analysts are cautious with a majority hold rating. Investors face a binary outcome: accept the premium bid or navigate ACB's volatile fundamentals.
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
